Acumen Pharmaceuticals Inc. (ABOS) Statistics & Valuation Metrics - Stocknear

Acumen Pharmaceuticals In...

NASDAQ: ABOS · Real-Time Price · USD
1.73
-0.04 (-2.26%)
At close: Oct 03, 2025, 3:59 PM
1.77
2.31%
After-hours: Oct 03, 2025, 06:27 PM EDT

Acumen Pharmaceuticals Statistics

Share Statistics

Acumen Pharmaceuticals has 60.57M shares outstanding. The number of shares has increased by 0.82% in one year.

60.57M
0.82%
0%
62.08%
46.91M
4,287
1.11%

Short Selling Information

The latest short interest is 1.36M, so 2.24% of the outstanding shares have been sold short.

1.36M
2.24%
3.02%
10.41

Valuation Ratios

The PE ratio is -1.01 and the forward PE ratio is -1.06. Acumen Pharmaceuticals's PEG ratio is -0.02.

-1.01
-1.06
0
n/a
0.57
-1.2
-0.02
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Acumen Pharmaceuticals.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.16.

6.46
6.46
0.16
-0.3
-0.34
-28.03

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1.68M
61
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by -27% in the last 52 weeks. The beta is 0.2, so Acumen Pharmaceuticals's price volatility has been higher than the market average.

0.2
-27%
1.41
1.33
66.19
386,100

Income Statement

n/a
-178K
-114.02M
-102.33M
-98.08M
-98.26M
-1.71
Full Income Statement

Balance Sheet

The company has 35.63M in cash and 29.7M in debt, giving a net cash position of 5.92M.

35.63M
29.7M
5.92M
-325.13M
171.9M
123.54M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -86.22M and capital expenditures -16K, giving a free cash flow of -86.23M.

-86.22M
-16K
-86.23M
-1.44
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

ABOS does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for ABOS is $6.5, which is 275.7% higher than the current price. The consensus rating is "Buy".

$6.5
275.7%
Buy
3
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

-3.95
2